ReviewDialogues in clinical neuroscience2006
Treatments in depression.
Review in Dialogues in clinical neuroscience, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Brain connectivity changes underlying depression and fatigue in relapsing-remitting multiple sclerosis: A systematic review.PloS one · 2024Pooled it
- Pooled it
- Wearable-Based Assessment for Relapse Prediction Following Repetitive Transcranial Magnetic Stimulation for Depression: Protocol for a Feasibility Study (WARN-D Study).JMIR research protocols · 2026Article
- Psilocybin-containing mushroom-assisted psychotherapy is associated with sustained psychological and somatic improvements: two case studies from Jamaica.Frontiers in psychiatry · 2026Article
- Depression in Chinese adolescents: prevalence, symptoms, risk factors, affected brain, diagnosis, and interventions.Frontiers in psychology · 2026Review
- Novel Insights into Dietary Bioactive Compounds and Major Depressive Disorders: Evidence from Animal Studies and Future Perspectives.The Journal of nutrition · 2025Review
- Review
- Depression diagnosis from patient interviews using multimodal machine learning.Frontiers in psychiatry · 2025Article
- A Bibliometric Analysis of Research on Natural Medicines for Depression from 2004 to 2024.Journal of multidisciplinary healthcare · 2025Article
- Prediction of molecular targets for antidepressant potential of hydroalcoholic extract of3 Biotech · 2024Article
- Transcranial Electrical Stimulation: Clinical Implication and Practice for Treatment of Psychiatric Illness.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2024Review
- Psilocybin, an Effective Treatment for Major Depressive Disorder in Adults - A Systematic Review.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2024Review
- Critical appraisal of evidence supporting prescription of psychedelics from clinic websites in Ontario, Canada.PloS one · 2024Article
- Evaluation of Antidepressive-like Behaviours and Oxidative Stress Parameters in Mice Receiving Imipramine-Zinc Complex Compound.International journal of molecular sciences · 2023Article
- Interventional Mental Health: A Transdisciplinary Approach to Novel Psychiatric Care Delivery.Cureus · 2023Review
- Overcoming Depression with 5-HTInternational journal of molecular sciences · 2021Review
- Investigation of Antidepressant Properties of Yohimbine by Employing Structure-Based Computational Assessments.Current issues in molecular biology · 2021Article
- Neuroendocrine Assessment of Dopaminergic Function during Antidepressant Treatment in Major Depressed Patients.Brain sciences · 2021Article
- Intranasal Nanoemulsions for Direct Nose-to-Brain Delivery of Actives for CNS Disorders.Pharmaceutics · 2020Review
- TASK-3 as a potential antidepressant target.Brain research · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Major depression is believed to be a multifactorial disorder involving predisposing temperament and personality traits, exposure to traumatic and stressful life events, and biological susceptibility. Depression, both unipolar and bipolar, is a "phasic" disease. Stressful life events are known to trigger depressive episodes, while their influence seems to decrease over the course of the illness. This suggests that depression is associated with progressive stress response abnormalities, possibly linked to impairments of structural plasticity and cellular resilience. It therefore appears crucial to adequately treat depression in the early stages of the illness, in order to prevent morphological and functional abnormalities. While evidence suggests that a severely depressed patient needs antidepressant drug therapy and that a non-severely depressed patient may benefit from other approaches (ie, "nonbiological"), little research has been done on the effectiveness of different treatments for depression. The assertion that the clinical efficacy of antidepressants is comparable between the classes and within the classes of those medications may be true from a statistical viewpoint, but is of limited value in practice. The antidepressant drugs may produce differences in therapeutic response and tolerability. Among the possible predictors of outcome in depression treatment, those derived from clinical assessment, neuroendocrine investigations, polysomnographic sleep parameters, genetic variables, and brain imaging techniques have been extensively studied. This article also reviews therapeutic strategies used when initial treatment fails, and describes briefly new concepts in antidepressant therapies such as the regulation of disturbances in circadian rhythms. The treatment of depressive illness does not stop with treatment of acute episodes, and has to be envisaged as a continuous therapeutic intervention, of which we are still not able to determine the optimal duration of treatment and the moment that it should be ceased.
Indexed as
Identifiers
16889105PMC3181767What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.